Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany-Reference-Cited by-同舟云学术

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany

Published:2021-09-06 Issue:11 Volume:43 Page:3540-3551
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Singh Prianka¹,McDonald Laura¹,Waldenberger Daniela²,Welslau Manfred³,Heyde Eyck⁴,Gauler Thomas⁵,Dietz Andreas⁶

Affiliation:

1. Health Economics Outcomes Research Bristol Myers Squibb Lawrenceville New Jersey USA

2. Medical Oncology Bristol Myers Squibb GmbH & Co. KGaA Munich Germany

3. Hämato‐Onkologische Schwerpunktpraxis, Klinikum Aschaffenburg Aschaffenburg Germany

4. Oncology Onkologische Praxis am Raschplatz Hannover Germany

5. Klinik für Strahlentherapie Universitätsklinikum Essen Essen Germany

6. Klinik und Poliklinik für Hals‐, Nasen‐, Ohrenheilkunde Universitätsklinikum Leipzig Leipzig Germany

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.26853

Reference31 articles.

1. Cancer.Net Head and Neck Cancer: Statistics.2020;https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics. Accessed May 20 2020.

2. Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis

3. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

4. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

5. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral epithelial dysplasia with lymphocytic immune response: clinicopathological characterisation of 44 cases;Histopathology;2024-03-18

2. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada;Journal of Immunotherapy;2024-01-17

3. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck;Frontiers in Oncology;2023-08-01

4. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma;Frontiers in Oncology;2023-05-22

5. Antibiotics Significantly Decrease the Survival of Head and Neck Carcinoma Patients with Immunotherapy: A Real-World Analysis of More Than 3000 Cases;Cancers;2023-04-18